This brand name is authorized in Malta
The drug RAXIVANOL contains one active pharmaceutical ingredient (API):
|
1
Rivaroxaban
UNII 9NDF7JZ4M3 - RIVAROXABAN
|
|
Rivaroxaban is a highly selective direct factor Xa inhibitor with oral bioavailability. Inhibition of factor Xa interrupts the intrinsic and extrinsic pathway of the blood coagulation cascade, inhibiting both thrombin formation and development of thrombi. Rivaroxaban does not inhibit thrombin (activated factor II) and no effects on platelets have been demonstrated. |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC code | Group title | Classification |
|---|---|---|
| B01AF01 | B Blood and blood forming organs → B01 Antithrombotic agents → B01A Antithrombotic agents → B01AF Direct factor Xa inhibitors | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| Country: MT | Medicines Authority | Identifier(s): MA240/03101, MA240/03102, MA240/03103 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
